Engaged Capital exited its stakes in BlackLine ( NASDAQ: BL) and Nevro ( NYSE: NVRO) and took a new position in Chart ...
2d
Zacks.com on MSNNevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy?Wall Street expects a year-over-year decline in earnings on lower revenues when Nevro (NVRO) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important ...
Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...
4d
GlobalData on MSNGlobus Medical strengthens SCS market position with $250m Nevro dealGlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...
7d
Zacks.com on MSNNevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro Corp (NVRO – Research Report) and Ansell (ANSLF – ...
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results